Sign Out
Sunitinib is indicated for the treatment of gastrointestinal stromal tumor (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.
Sunitinib is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (MRCC).
Sunitinib is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) with disease progression.
Sunitinib is indicated for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.
Continue with Google